3D-Printed Breast Implants Could Be the Next Big Thing in Plastic Surgery

Two German companies have paired up on the development of a technology that could disrupt the breast implant market. BellaSeno will use Evonik's Resomer bioresorbable polymer in its Senella breast scaffolds with a proprietary additive manufacturing process that avoids the use of silicone implants, some of which have raised major safety concerns. BellaSeno plans to begin first-in-human clinical trials of the Senella scaffolds with Resomer in Germany this quarter. Evonik has agreed to supply its Resomer polymer for clinical and commercial use. The scaffolds are designed to guide the growth of natural tissue using the patient's own body fat harvested via liposuction. Designed to be implanted after breast reconstruction, augmentation, or revision surgery, the Resomer polymer features mechanical properties and a degradation profile that allow the scaffold to absorb at a rate that matches the formation of the patient’s own tissue. Scaffolds will be available in different sizes and shapes to match the patients’ needs, BellaSeno said. Earlier this year BellaSeno obtained ISO 13485 certification for the design and additive manufacturing of resorbable implants. The company also offers integrated contract additive manufacturing deals (from concept and in-house design to manufacturing of prototypes, clinical trials, and series production) to other companies seeking to bring their own resorbable implants to market for a wide range of medical...
Source: MDDI - Category: Medical Devices Authors: Tags: 3-D Printing Source Type: news

Related Links:

Roche today announced new data on two investigational CD20-CD3 T-cell engaging bispecific antibodies, mosunetuzumab and CD20-TCB, in people with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Authors: Blakely CM, Riess JW Abstract Introduction: Lung cancer is the leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancer cases. The continued advancement of DNA sequencing technology and the discovery of multiple specific driver mutations underlying many cases of NSCLC are moving clinical intervention toward a more targeted approach. Here we focus on anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, as an oncogenic driver in NSCLC. The ALK gene is rearranged in 3-7% of NSCLCs, and targeted inhibition ...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Sirtuin-1 (Sirt-1), an NAD-dependent deacetylase, promotes tumorigenesis in glioma; however, whether the Sirt-1 specific inhibitor, EX527 exerts antitumor effects and the underlying mechanism in glioma requires further investigation. In the present study, the proliferative and colony formation abilities of two glioma cell lines (U87MG and LN-299) were inhibited by EX527. Treatment with EX527 increased the number of apoptotic cells (Annexin V-fluorescein isothiocyanate+/propidium iodide+/−); pretreatment with the caspase inhibitor Z-VAD-FMK suppressed EX527-induced apoptosis, suggesting that EX527 induced caspase-depe...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
We report the case of a 53-year-old woman affected by metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who received ALK tyrosine kinase inhibitors, from January 2017. The patient had a complete response of choroidal metastasis after therapy with ALK tyrosine kinase inhibitors. She recovered a complete visus and actually she still continue therapy with alectinib. The patient had a complete recovery of visus in addiction to a long response on treatment.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
CONCLUSIONS: In all the instances, statistical analysis showed that mean mSWAT score before/after SN diagnosis had a significantly difference (p value=0.0037) suggesting that patients with a SN may have a worse clinical outcome. By secreting immunosuppressive cytokines or recruiting immunosuppressive cells, a sort of mutual help between the two neoplasms may be prompted. Our data suggest that SN development in MF patients may be regarded as a worse prognostic marker. PMID: 31804054 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
(University of Pennsylvania School of Medicine) A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conditions:   Leukemia;   Lymphoma;   Blood Cancer;   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia;   Non-Hodgkins Lymphoma Intervention:   Other: Bone Marrow Transplant (BMT) Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Institutes of Health (NIH);   National Institute on Aging (NIA) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(University of Texas Health Science Center at San Antonio) A new class of drugs degrades an essential survival protein in cancer cells while sparing platelets. Therefore, it could be a safer therapy for multiple types of leukemia and lymphoma, say researchers at UT Health San Antonio.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Abnormal activation of the classic Wnt signaling pathway is closely related to the occurrence of epithelial cancers. B-cell lymphoma 9 (BCL9), a transcription factor, is a novel oncogene discovered in the clas...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
Kathy Desclefs, of Jacksonville, Florida, has been battling non-Hodgkin's lymphoma for five years. This year, her husband Benoit and her son Luke were also diagnosed with cancer.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Breast Augmentation | Cancer | Cancer & Oncology | Clinical Trials | Contracts | Dialysis | France Health | Germany Health | Liposuction | Lymphoma | Medical Devices | Plastic Surgery | Women